Topics
High-grade gliomas | Treatment | Targeted therapy | Ipilimumab
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Ipilimumab
Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L,
Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H,
Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S,
Neyns B.
Intracranial administration
of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal
antibodies in patients with recurrent high-grade glioma.
Neuro
Oncol. 2024 Oct 16:noae177. doi:
10.1093/neuonc/noae177. PMID:
39406392. Interventional study. ˍ
Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA,
Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang
SC, Barkhoudarian G, Kelly DF, Juarez TM.
Pre-radiation
Nivolumab plus ipilimumab in patients with
newly diagnosed high-grade gliomas.
Oncoimmunology.
2024 Nov 21;13(1):2432728. doi:
10.1080/2162402X.2024.2432728. PMID:
39572979. Interventional study. ˍ